

REQUEST FOR CONTINUED EXAMINATION (RCE) TRANSMITTAL Subsection (b) of 35 U.S.C. § 132, effective on May 29, 2000, provides for continued examination of an utility or plant application filed on or after June 8, 1995. See The American Inventors Protection Act of 1999 (AIPA).	<i>Application Number</i>	13/034,340
	<i>Filing Date</i>	February 24, 2011
	<i>First Named Inventor</i>	Alan H. Auerbach
	<i>Group Art Unit</i>	1628
	<i>Examiner Name</i>	San Ming R. Hui
	<i>Attorney Docket Number</i>	CGR5001USCNT1

This is a Request for Continued Examination (RCE) under 37 C.F.R. § 1.114 of the above-identified application.

NOTE: 37 C.F.R. § 1.114 is effective on May 29, 2000. If the above-identified application was filed prior to May 29, 2000, applicant may wish to consider filing a continued prosecution application (CPA) under 37 C.F.R. § 1.53 (d) (PTO/SB/29) instead of a RCE to be eligible for the patent term adjustment provisions of the AIPA. See *Changes to Application Examination and Provisional Application Practice*, Final Rule, 65 Fed. Reg. 50092 (Aug. 16, 2000); Interim Rule, 65 Fed. Reg. 14865 (Mar. 20, 2000), 1233 Off. Gaz. Pat. Office 47 (Apr. 11, 2000), which established RCE practice.

1. **Submission required under 37 C.F.R. § 1.114**

- a. Previously submitted
- i. Consider the amendment(s)/reply under 37 C.F.R. § 1.116 previously filed on (any unentered amendment(s) referred to above will be entered).
- ii. Consider the arguments in the Appeal Brief or Reply Brief previously filed on
- iii. Other
- b. Enclosed
- i. Amendment/Reply
- ii. Affidavit(s)/Declaration(s)
- iii. Information Disclosure Statement (IDS)
- iv. Other

2. **Miscellaneous**

- a. Suspension of action on the above-identified application is requested under 37 C.F.R. § 1.103(c) for a period of months. (Period of suspension shall not exceed 3 months; Fee under 37 C.F.R. § 1.17(i) required.)
- b. Other

3. **Fees** - The RCE fee under 37 C.F.R. § 1.17(e) is required by 37 C.F.R. § 1.114 when the RCE is filed

- a. The Director is hereby authorized to charge the following fees, or credit any overpayments, to Deposit Account No. **10-0750**.
- i. RCE fee is required under 37 C.F.R. § 1.17(e)
- ii. Extension of Time (37 C.F.R. §§ 1.136 and 1.17)
- iii. Other
- b. Check in the amount of \$ _____ enclosed
- c. Payment by credit card (Form PTO-2038 enclosed)

SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT REQUIRED

Name (print/type)	Andrea Jo Kamage	Registration No.	43,703
Signature	/Andrea Jo Kamage/	Date	January 11, 2013

CERTIFICATE OF TRANSMISSION

I hereby certify that this correspondence is being electronically filed via EFS-Web to the Commissioner for Patents with the U.S. Patent and Trademark Office on: January 11, 2013

Name (print/type)	Laurie A. Phillips	Date	January 11, 2013
Signature	/Laurie A. Phillips/		

I hereby certify that this correspondence is being transmitted via The Office Electronic Filing System (EFS) in accordance with 37 CFR 1.6(a)(4).

Date of Electronic (EFS) Transmission: January 11, 2013

Signature: /Laurie A. Phillips/ Name: Laurie A. Phillips

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:

Applicant(s):	Alan H. Auerbach	Conf. No.:	1597
Application No.:	13/034,340	Group Art:	1628
Filing Date:	February 24, 2011	Examiner:	San Ming R. Hui
Title:	Methods and Compositions for Treating Cancer		

Mail Stop Amendment
 Commissioner for Patents
 P.O. Box 1450
 Alexandria, VA 22313-1450

RESPONSE

Dear Sir:

In response to the final Office Action mailed September 11, 2012, Applicants submit the following amendments and remarks.

A list of the Claims are reflected in the listing of claims, which begins on page 2 of this paper.

Remarks/Arguments begin on page 4 of this paper.

Listing of Claims:

1-36. (Canceled).

37. (Previously presented) A method for the treatment of a prostate cancer in a human comprising administering to said human a therapeutically effective amount of abiraterone acetate or a pharmaceutically acceptable salt thereof and a therapeutically effective amount of prednisone.

38. (Previously presented) The method of claim 37, wherein the therapeutically effective amount of the abiraterone acetate or pharmaceutically acceptable salt thereof is from about 50 mg/day to about 2000 mg/day.

39. (Previously presented) The method of claim 38, wherein the therapeutically effective amount of the abiraterone acetate or pharmaceutically acceptable salt thereof is from about 500 mg/day to about 1500 mg/day.

40. (Previously presented) The method of claim 39, wherein the therapeutically effective amount of the abiraterone acetate or pharmaceutically acceptable salt thereof is about 1000 mg/day.

41. (Previously presented) The method of claim 37, wherein the therapeutically effective amount of the abiraterone acetate or a pharmaceutically acceptable salt thereof is administered in at least one dosage form comprising about 250 mg of abiraterone acetate or a pharmaceutically acceptable salt thereof.

42. (Previously presented) The method of claim 37, wherein the therapeutically effective amount of the prednisone is from about 0.01 mg/day to about 500 mg/day.

43. (Previously presented) The method of claim 42, wherein the therapeutically effective amount of the prednisone is from about 10 mg/day to about 250 mg/day.

44. (Previously presented) The method of claim 44, wherein the therapeutically effective amount of the prednisone is about 10 mg/day.

45. (Previously presented) The method of claim 37, wherein the therapeutically effective amount of the prednisone is administered in at least one dosage form comprising about 5 mg of prednisone.

46. (Previously presented) The method of claim 37, comprising administering to said human about 500 mg/day to about 1500 mg/day of abiraterone acetate or a pharmaceutically acceptable salt thereof and about 0.01 mg/day to about 500 mg/day of prednisone.

47. (Previously presented) The method of claim 46, comprising administering to said human about 1000 mg/day of abiraterone acetate or a pharmaceutically acceptable salt thereof and about 10 mg/day of prednisone.

48. (Previously presented) The method of claim 37, wherein said prostate cancer is refractory prostate cancer.

49. (Previously presented) The method of claim 48, wherein the refractory prostate cancer is not responding to at least one anti-cancer agent.

50. (Previously presented) The method of claim 49, wherein the at least one anti-cancer agent comprises a hormonal ablation agent, an anti-androgen agent, or an anti-neoplastic agent.

51. (Previously presented) The method of claim 50, wherein the hormonal ablation agent comprises deslorelin, leuprolide, goserelin, or triptorelin.

52. (Previously presented) The method of claim 50, wherein the anti-androgen agent comprises bicalutamide, flutamide, or nilutamide.

53. (Previously presented) The method of claim 50, wherein the anti-neoplastic agent comprises docetaxel.

Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.